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Abstract
The purpose of this study was to evaluate the effects of a thermogenic supplement, Meltdown, on
energy expenditure, fat oxidation, and hemodynamics before and after maximal treadmill exercise.
In a double-blind, randomized, placebo-controlled, cross-over design, 12 male participants
underwent two testing sessions after consuming either the Meltdown or placebo supplement.
While in a fasted state, participants rested for one hour, orally ingested either Meltdown or placebo
and rested for another hour, performed a maximal treadmill exercise test, and then rested for
another hour. Throughout the testing protocol, resting energy expenditure (REE) and respiratory
exchange ratio (RER) were assessed. In addition, heart rate (HR) and blood pressure (BP) were
assessed before and after exercise. Meltdown increased REE significantly more than placebo at 45
min (1.44 ± 0.25 vs. 1.28 ± 0.23 kcal/min; p = 0.003), 60 min (1.49 ± 0.28 vs. 1.30 ± 0.22 kcal/min;
p = 0.025), and 120 min (1.51 ± 0.26 vs. 1.33 ± 0.27 kcals/min; p = 0.014) post-ingestion. Meltdown
significantly decreased RER at 30 min (0.84 ± 0.03 vs. 0.91 ± 0.04; p = 0.022) and 45 min post-
ingestion (0.82 ± 0.04 vs. 0.89 ± 0.05; p = 0.042), and immediately post-exercise (0.83 ± 0.05 vs.
0.90 ± 0.07; p = 0.009). Furthermore, over the course of the evaluation period, area under the
curve assessment demonstrated that REE was significantly increased with Meltdown compared to
placebo (992.5 ± 133.1 vs. 895.1 ± 296.1 kcals; p = 0.043), while RER was significantly less than
placebo (5.55 ± 0.61 vs. 5.89 ± 0.44; p = 0.002) following ingestion. HR and BP were not significantly
affected prior to exercise with either supplement (p > 0.05) and the exercise-induced increases for
HR and BP decreased into recovery and were not different between supplements (p > 0.05). These
data suggest that Meltdown enhances REE and fat oxidation more than placebo for several hours
after ingestion in fully rested and post-exercise states without any adverse hemodynamic responses
associated with maximal exercise.
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Background
Despite a restructured food guide pyramid, ambitious
Healthy People 2010 guidelines, and an explosion of
weight loss products, there is an absence of systemic obes-
ity relief. In fact, obesity is a growing concern and the
problem may be accelerating. According to the CDC and
results from the Behavioral Risk Factor Surveillance Sys-
tem (BRFSS) survey, obesity rates grew from 19.8% in
2000 to 23.9% in 2005, which is an increase of about
0.82% per year; obesity grew from 23.9% in 2005 to
25.6% in 2007, representing a 0.9% yearly increase [1].
The ramifications of the escalating obesity epidemic
include an increased incidence of chronic disease and
annual health care expenditure, as well as lost productiv-
ity [2].
Consumers often ingest diet products to bolster weight
loss efforts. Formerly, ephedrine and ephedra were inte-
gral components in weight loss supplements. Since the
most substantial effect of ephedrine use is enhanced sym-
pathetic nervous system (SNS) activity via increased nore-
pinephrine (NE) release from the nerve terminal, the drug
has an impact on all adrenergic receptors (AR). Moreover,
the ephedrine compound also has β-AR agonist and α-AR
antagonist activity in circulation [3]. Previous investiga-
tions indicate that supplemental weight loss products
containing a combination of ephedra (ma huang) or ephe-
drine and caffeine increase resting energy expenditure
(REE) and loss of fat mass [4-6]. Therefore, prudent sup-
plementation with ephedra-containing products, in com-
bination with a sensible diet and exercise plan, has the
potential to accelerate weight loss.
On April 12, 2004, however, ephedra-containing products
were condemned by the FDA in response to safety con-
cerns; therefore, manufacturers of nutrition supplements
sought to formulate alternative thermogenic weight loss
products with comparable effectiveness. As such, supple-
ments containing caffeine and β-agonist compounds sim-
ilar to ephedra began to appear on the market. Therefore,
the  Citrus aurantium-derived alkaloids synephrine and
octapamine have gained popularity. Meltdown is a ther-
mogenic product that combines synephrine, caffeine,
phenylethylamine, yohimbine, hordenine and other
compounds to stimulate the β-AR, thereby activating
cyclic AMP (cAMP), while also inhibiting the α-AR that
illicit an inhibitory response.
Activation of the SNS neurons stimulates the release of
two primary catecholamine signaling molecules, epine-
phrine (E) and NE. After NE acts as an SNS stimulatory
neurotransmitter (NT) in the brain, the adrenal medulla is
prompted to release NE into blood. E or NE binding to an
AR will produce a range of responses, the nature of the
response depends upon on the receptor subtype to which
the hormone binds [7].
Adrenergic analogues utilized in a thermogenic supple-
ment are likely to enhance the activation of the SNS. For
instance, the compound synephrine, which structurally
resembles ephedrine, is primarily a sympathomimetic α1-
AR agonist [8]. Typically, activation of the α1-AR mainly
results in smooth muscle contraction, which causes vaso-
constriction in blood vessels of the skin, GI tract, kidney
and brain. Furthermore, one study revealed that syne-
phrine also has moderate non-selective β3-AR agonist
activity in several cell lines [9]. As previously revealed by
Weyer et al. [10], supplementation with a selective β3-AR
agonist, specifically CL 316,243, stimulates lipolysis in
healthy men. Therefore, if synephrine is a sufficiently
potent β3-AR agonist, the compound may promote fat
and weight loss in humans through enhanced lipolysis in
adipose tissue.
Caffeine is also a popular addition to thermogenic com-
pounds, and two of the effects of caffeine are particularly
relevant. Specifically, caffeine serves as an antagonist to
adenosine in the neurons, via competitive inhibition,
which stimulates the SNS [11]. Therefore, NE, dopamine
and GABA secretion are increased in the brain, which
prompts a greater release of catecholamines into the sys-
temic circulation. Furthermore, since caffeine is also a
known non-selective inhibitor of the enzyme cAMP-phos-
phodiesterase (PDE), which converts cAMP to its inactive,
non-cyclic form, the compound amplifies the signal of
cAMP through inhibition of PDE [12]. By promoting high
concentrations of cAMP, caffeine intensifies and prolongs
the effects of E and NE, as well as other stimulatory AR
agonists, such as synephrine and octopamine. The ther-
mogenic additive phenylethylamine also inhibits the
reuptake of NE from the synaptic cleft [13]. Finally,
yohimbine acts as a α2-AR antagonist [14]. Since α2-AR
exist on the adrenal medulla as a negative feedback system
for catecholamine release, a α2-AR antagonist may be of
benefit in a weight loss supplement as a permissive pro-
moter of NE and E release and signaling [15]. Finally,
hordenine, like ephedrine, may have non-specific effects
on AR by stimulating the release of NE [16], though
human data is lacking.
When these compounds are combined in supplement
form, they may work synergistically to enhance weight
loss. Initially, phenylethylamine, caffeine, and hordenine
may stimulate the SNS in a non-specific manner. Once
SNS stimulation is initiated, N and NE circulate in higher
than normal amounts, which activate AR throughout the
body. Simultaneously, the inhibitory effects of the α2-AR
are blocked by yohimbine. Furthermore, stimulatory SNS
responses are enhanced by synephrine, which promotesJournal of the International Society of Sports Nutrition 2008, 5:23 http://www.jissn.com/content/5/1/23
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the activity of Gs and subsequent cAMP signaling cas-
cades. Finally, caffeine potentiates all cAMP activity by
specifically inhibiting PDE.
The purpose of this study was to determine the effects of a
single dose of the thermogenic supplement, Meltdown,
on markers of hemodynamic function and energy expend-
iture at rest and during recovery from intense cardiovascu-
lar exercise. Therefore, the specific aims of this study were
to assess the effects of Meltdown on: 1) REE for one hour
prior to and one hour following a single bout of intense
treadmill exercise and 2) hemodynamic and metabolic




Twelve apparently healthy and recreationally active male
volunteers (23.67 +/- 4.66 yr, 175.05 +/- 7.16 cm, 79.89
+/- 18.01 kg) who were mild caffeine users (approxi-
mately 80 mg caffeine/day) participated in the study. All
participants were cleared for participation by passing a
mandatory medical screening. Participants with contrain-
dications to exercise as outlined by the American College
of Sports Medicine or who had consumed any nutritional
supplements (excluding multi-vitamins) for two months
prior to the study were not allowed to participate. All par-
ticipants provided oral and informed written consent
based on university-approved documents approved by the
Institutional Review Board for Human Subjects for the
Protection of Humans in Research. Additionally, all exper-
imental procedures conformed to the ethical guidelines of
the Helsinki Code. The purpose of the research and exper-
imental procedures were explained to all study partici-
pants.
Experimental protocol
In a double-blind, placebo-controlled, cross-over design,
participants participated in two testing sessions after con-
suming either the Meltdown or placebo supplement. At
each testing session, participants rested during a baseline
assessment of REE for one hour, during which time respi-
ratory exchange ratio (RER) was also determined as an
indicator of macronutrient oxidation. At the conclusion of
the resting/baseline measurements, participants orally
ingested 3 capsules (500 mg) of Meltdown (Vital Pharma-
ceuticals, Davie, FL) or 3 capsules of cellulose placebo
(500 mg) based on random assignment. Specifically,
three capsules of Meltdown contains the following: 317
mg of a proprietary blend of caffeine anhydrous, α-methyl
tetradecylthioacetic acid, yerba mate extract, and cAMP;
20 mg of methyl-synephrine HCl, 138 mg of a proprietary
blend of β-methylphenylethylamine and methyl-β-phe-
nylethylamine; 9 mg of a proprietary blend of 11-hydroxy
yohimbine, yohimbine HCl, and α-yohimbine; 20 mg of
methyl-hordenine HCl. Upon ingesting the supplement,
the participants rested during another hour of REE meas-
urement, during which time REE and RER were assessed
every 15 min. At this point, participants performed a max-
imal aerobic treadmill test employing the Bruce protocol
to assess their VO2max values using an open circuit spirom-
etry system (Parvo Medics, Sandy, UT); HR and BP was
assessed before and immediately following the exercise
test. Upon completion of the exercise test, participants
entered a one-hour recovery period in which REE and
RER, were determined every 15 min.
Dietary records
The participants' diets were not standardized and were
asked not to change their dietary habits during the course
of the study. However, subjects were required to keep die-
tary records for 48 hours prior to each testing session. The
48-hour dietary records were evaluated with the Food
Processor dietary assessment software program to deter-
mine the average daily macronutrient consumption of fat,
carbohydrate, and protein in the diet prior to supplemen-
tation and exercise.
Resting energy expenditure test
Prior to and following exercise, participants rested supine
on a padded table. Throughout the test, the participants
had their expired gases monitored continuously for one
hour throughout the test to determine REE and RER as an
estimate of substrate oxidation using the using the 2400
TrueMax Metabolic Measurement System (Parvo Medics,
Sandy, Utah).
Assessment of Hemodynamic Variables (Heart Rate & 
Blood Pressure)
Prior to, during, and following exercise, participants'
hemodynamic safety markers (HR and BP) were moni-
tored. Heart rate was determined by a Polar heart rate
monitor, and blood pressure was assessed in the supine
position with a mercurial sphygmomanometer using
standard procedures.
Aerobic exercise capacity test
Participants completed maximal exercise on a treadmill
(Quinton Q-Stress TM65, Bothell, WA) utilizing the Bruce
protocol. The participants breathed through a sanitized
mouthpiece attached to a head harness and a nose-clip.
Throughout the test, expired gases were collected using
the 2400 TrueMax Metabolic Measurement System (Parvo
Medics, Sandy, Utah) during the warm-up and through-
out exercise to exhaustion. During exercise, HR, BP, RER,
and VO2max were determined.
Statistical analyses
Statistical analyses were performed by utilizing separate 2
× 6 [Supplement (Meltdown, placebo] × Test (pre-rest,Journal of the International Society of Sports Nutrition 2008, 5:23 http://www.jissn.com/content/5/1/23
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post-rest, pre-exercise, post, exercise, pre-recovery, post-
recovery) factorial analyses of variance (ANOVA) with
repeated measures for each criterion variable. Significant
between-group differences were determined involving the
Neuman-Keuls Post Hoc Test. However, to protect against
Type I error, the conservative Hunyh-Feldt Epsilon correc-
tion factor was used to evaluate observed within-group F-
ratios. In addition, area under the curve (AUC) was calcu-
lated by integral calculus for REE and RER. A Student's
paired t-test was performed on the AUC for REE and RER
and also for VO2max. All statistical procedures were per-
formed using SPSS 11.0 software and a probability level of
< 0.05 was adopted throughout.
Results
Hemodynamic variables (HR and BP) were not signifi-
cantly affected prior to exercise with either supplement (p
> 0.05) and the expected exercise-induced increases
observed in HR and BP that decreased into recovery were
not different between supplements (p > 0.05). Relative to
any supplement-induced differences in exercise perform-
ance, VO2max assessed at each of the testing sessions dem-
onstrated no significant differences between Meltdown
and placebo (45.31 ± 6.10 vs. 41.69 ± 9.98 ml O2/kg/min,
p = 0.185).
Meltdown increased REE significantly more than placebo
at 45 min (1.44 ± 0.25 vs. 1.28 ± 0.23 kcal/min; p = 0.003)
and 60 min (1.49 ± 0.28 vs. 1.30 ± 0.22 kcal/min; p =
0.025) post-ingestion. Furthermore, REE 60 min post-
exercise (120 min following supplement administration)
was significantly higher in the Meltdown group (1.51 ±
0.26 vs. 1.33 ± 0.27 kcals/min; p = 0.014) (Figure 1). Over
the course of the evaluation period, AUC analysis demon-
strated that REE was significantly increased with Melt-
down compared to placebo (992.5 ± 133.1 vs. 895.1 ±
296.1 kcals; p = 0.043) (Figure 2).
Meltdown significantly decreased RER, compared to pla-
cebo, at 30 min (0.84 ± 0.03 vs. 0.91 ± 0.04; p = 0.022)
and 45 min post-ingestion (0.82 ± 0.04 vs. 0.89 ± 0.05; p
= 0.042), and immediately post-exercise (0.83 ± 0.05 vs.
0.90 ± 0.07; p = 0.009) (Figure 3). Furthermore, over the
course of the evaluation period, AUC analysis demon-
strated that RER significantly decreased with Meltdown
compared to placebo (5.55 ± 0.61 vs. 5.89 ± 0.44; p =
0.002) (Figure 4).
Discussion
The purpose of the present study was to determine the
effects of Meltdown, a commercially available ther-
mogenic nutritional supplement, on HR, BP, REE, and
RER before, during, and after exercise. The results of this
study show that Meltdown supplementation significantly
elevated REE up to 120 min post-ingestion, while also
decreasing RER up to 60 min post-ingestion. However, no
significant differences were observed between Meltdown
and placebo after a bout of maximal treadmill exercise,
which was conducted 75 minutes after supplementation.
In addition, no significant differences between Meltdown
and placebo were observed for HR or BP before, during, or
after exercise. Therefore, the symathomimetic compounds
within Meltdown were not associated with any differen-
tial effects on hemodynamic function during exercise.
An illustration of the effects of Meltdown and placebo on  REE over the course of the evaluation period Figure 1
An illustration of the effects of Meltdown and pla-
cebo on REE over the course of the evaluation 
period. * indicates that Meltdown significantly elevated REE 
at 45 min (p = 0.003) and 60 min post-ingestion (p = 0.025), 
and at 60 min post-exercise (p = 0.014). Data are presented 
as means ± SD.
Area under the curve analysis demonstrated that Meltdown  significantly increased REE compared to placebo (p = 0.043) Figure 2
Area under the curve analysis demonstrated that 
Meltdown significantly increased REE compared to 
placebo (p = 0.043). Data are presented as means ± SD.Journal of the International Society of Sports Nutrition 2008, 5:23 http://www.jissn.com/content/5/1/23
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Thermogenic supplements may increase REE and fat
metabolism through activation of the β2 and β3-AR. β2-
AR stimulation has also been shown to up-regulate
uncoupling proteins in skeletal muscle, which may have a
significant impact on whole body thermogenesis [17,18].
Furthermore, the β3-AR, located primarily on adipocytes,
enhances lipolysis and thermogenesis. It has been deter-
mined that beta-AR agonists with high thermogenic,
antiobesity, and antidiabetic activities are potent stimula-
tors of the β3-AR [19]. Given that the stimulation of the
β3-AR primarily promotes lipolysis, it appears to be a
good target for weight management and obesity treat-
ment.
Previous studies examining the efficacy and safety of sev-
eral alleged thermogenic compounds such as caffeine, cit-
rus aurantium, garcinia cambogia, green tea extract, and
ephedra have been conducted [5,6,12,20-24]. Moreover,
studies involving ephedra or ephedra/caffeine revealed
that that these compounds, especially in combination,
may have significant potential to increase daily energy
expenditure. In fact, the ephedrine/caffeine combination
is reported to increase energy use 37.4–114 kcal/day more
than placebo [21-24]. For example, one study investigated
the changes in REE for three hours following the adminis-
tration of 150 mg of caffeine and herbal ephedra contain-
ing 20 mg of ephedrine alkaloids [20]. During the final 30
min of measurement, REE was 8.5 ± 2.0% higher (P <
0.05) in the caffeine/ephedra trial compared to the pla-
cebo trial. A significant increase in REE was observed for
caffeine/ephedra 180 min post-ingestion (1.47 ± 0.10 vs.
1.34 ± 0.08 kcal/min). In the present study, Meltdown
supplementation, as compared to placebo, induced an
increase in REE at 60 min post-supplementation (1.49 ±
0.28 vs. 1.30 ± 0.22 kcal/min) comparable to the previ-
ously-mentioned ephedra/caffeine study [20]. Since Melt-
down contains compounds with β-agonist activity, in
comparison to previous studies [21-24] Meltdown may
generate REE increases comparable to ephedrine, even
though in the present study the increases were observed to
occur approximately 120 minutes earlier.
Furthermore, another study revealed that Java Fit, a com-
bination herb and coffee supplement product, containing
green tea extract, garcinia cambogia and niacin, produced
a 14.4% increase (1,858.23 ± 412.89 vs. 2179.75 ± 424.34
kcal/day or 1.29 ± 0.29 vs. 1.51 ± 0.29 kcal/min) over the
baseline resting energy expenditure value three hours after
administration in physically active adults [25]. This differ-
ence was significantly more than a 5.7% increase observed
with a commercially available caffeine-containing coffee.
On the other hand, no significant changes were observed
in RER during this study, and no significant changes in HR
or BP were observed for either coffee product. In addition,
another study conducted with Java Fit coffee concluded
that this product has no negative effect on hemodynamic
function and may increase REE in individuals who are
sensitive to caffeine and herbs contained within the coffee
supplement [26]. Therefore, the results of these two stud-
ies indicate that a mixed herbal product containing caf-
feine, green tea extract, garcinia cambogia and niacin
induced a significant increase in energy expenditure with-
out a simultaneous increase in hemodynamic safety vari-
ables in a young, fit population.
An illustration of the effects of Meltdown and placebo on  RER over the course of the evaluation period Figure 3
An illustration of the effects of Meltdown and pla-
cebo on RER over the course of the evaluation 
period. * indicates that Meltdown significantly decreased 
RER at 30 min (p = 0.022) and 45 min post-ingestion (p = 
0.042), as well as immediately post-exercise (p = 0.009). Data 
are presented as means ± SD.
Area under the curve analysis demonstrated that Meltdown  significantly decreased RER compared to placebo (p = 0.002) Figure 4
Area under the curve analysis demonstrated that 
Meltdown significantly decreased RER compared to 
placebo (p = 0.002). Data are presented as means ± SD.Journal of the International Society of Sports Nutrition 2008, 5:23 http://www.jissn.com/content/5/1/23
Page 6 of 7
(page number not for citation purposes)
In addition to overall energy use, the use of fat as a source
of energy, as indicated by an RER close to 0.7, is also of
interest in metabolic studies. Furthermore, greater use of
fat as an energy source is also presumed to be favorable.
In fact, a study of 775 healthy, non-obese young men
revealed that a high fasting RER (> 0.86) is a predictor of
weight gain in men with an initial BMI < 25 [27]. There-
fore, a product that lowers RER may be beneficial for lean
men. Respiratory exchange ratio was significantly
decreased with Meltdown, as determined by AUC analy-
sis. Since REE increased and RER decreased, the data sug-
gest that the Meltdown supplement increased energy
expenditure with a reliance on fat as the preferential
source of substrate oxidation.
Though ephedra and caffeine combination products
increase metabolic activity [21-24], products of this kind
are also associated with increases in blood pressure and
heart rate. For example, one study of 15 healthy, young
(aged 26.7 ± 2.52 years) male and female participants
revealed that a single dose of a Metabolife 356, which
included 12 mg of ephedra and 40 mg of caffeine, resulted
in increases in the mean maximal QTc interval and systo-
lic BP. As such, there is concern that combination prod-
ucts designed to mimic the effects of the ephedra and
caffeine will also cause significant increases in HR and BP
[28]. Such an increase in HR and BP was observed in a
study comparing placebo to Xenadrine EFX, a 19-compo-
nent combination product containing both caffeine and
synephrine [29]. Therefore, the concern that so-called
ephedra-free thermogenic products may increase BP
appears to be legitimate; however, the results of the
present study do not suggest that Meltdown increases
hemodynamic safety markers. On the other hand, the
present study was conducted in apparently healthy, lean
young men; therefore, the results may not translate to
obese or morbid populations.
On the other hand, the individual components used in
thermogenic supplement formulation often do not have
significant effects on BP or HR. For instance, a previous
study also showed that a 46.9 mg dose of synephrine
alone does not raise BP or HR more than placebo in
healthy adults [29]. Though caffeine is thought to have a
pressor effect, as evidenced by some reviews and meta-
analysis [30,31], previous research indicates that caffeine
alone may not increase the HR or BP of healthy, young,
non-obese participants aged 21–26 [31]. Specifically, dur-
ing one investigation 11 male and female participants
ingested a caffeine dose of 5 mg/kg body weight or pla-
cebo [32]. The caffeine dose caused notable side effects
and a significant inotropic effect (as assessed by echocar-
diogram); however, no increases in HR or BP were
observed. On the other hand, another study of 10 healthy
men aged 21–39 showed that a bolus dose of 0.125 mg/
kg dose of yohimbine increased BP significantly [33];
however, HR was not affected. In the present study, the
Meltdown supplement did not significantly elevate HR
and BP before, during, or after exercise, which suggests
that ingestion of this thermogenic supplement does not
appear to adversely affect hemodynamic responses.
In conclusion, these data presented herein suggest that
Meltdown enhances fat oxidation and REE more than pla-
cebo for up to 60 min and 120 min, respectively, after
ingestion in fully rested and post-exercise states without
any adverse hemodynamic responses when administered
to apparently healthy young men.
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